Symbols / CLNN Stock $6.57 +3.96% Clene Inc.
CLNN (Stock) Chart
About
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Stock Fundamentals
Scroll to Statements| Market Cap | 77.38M | Enterprise Value | 93.87M | Income | -26.17M | Sales | 200.00K | Book/sh | -1.62 | Cash/sh | 0.44 |
| Dividend Yield | — | Payout | 0.00% | Employees | 76 | IPO | — | P/E | — | Forward P/E | -4.52 |
| PEG | — | P/S | 386.92 | P/B | -4.05 | P/C | — | EV/EBITDA | -4.35 | EV/Sales | 469.34 |
| Quick Ratio | 0.54 | Current Ratio | 0.83 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -2.65 | EPS next Y | -1.46 |
| EPS Growth | — | Revenue Growth | -15.40% | Earnings | 2026-03-12 | ROA | -63.46% | ROE | — | ROIC | — |
| Gross Margin | 78.50% | Oper. Margin | -97.34% | Profit Margin | 0.00% | Shs Outstand | 11.78M | Shs Float | 8.43M | Short Float | 11.37% |
| Short Ratio | 11.35 | Short Interest | — | 52W High | 13.50 | 52W Low | 2.28 | Beta | 0.62 | Avg Volume | 81.30K |
| Volume | 80.34K | Target Price | $30.33 | Recom | None | Prev Close | $6.32 | Price | $6.57 | Change | 3.96% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-13 | main | Canaccord Genuity | Buy → Buy | $48 |
| 2026-03-12 | main | D. Boral Capital | Buy → Buy | $23 |
| 2026-01-09 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-12-10 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-12-03 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-09-10 | main | Benchmark | Buy → Buy | $31 |
| 2025-08-21 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-08-18 | main | Canaccord Genuity | Buy → Buy | $48 |
| 2025-08-14 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-07-18 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-06-30 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-05-08 | main | Benchmark | Buy → Buy | $33 |
| 2025-05-08 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-04-23 | init | Jones Trading | — → Buy | $30 |
| 2025-04-08 | main | D. Boral Capital | Buy → Buy | $23 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-25 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
- Is Clene (CLNN) stock worth entering at this stage | Q4 2025: EPS Misses Estimates - Trending Social Stocks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 05
- Clene (NASDAQ: CLNN) 10% holder SymBiosis II sells 65,663 shares - Stock Titan Wed, 22 Apr 2026 21
- When Will Clene Inc. (NASDAQ:CLNN) Turn A Profit? - Yahoo Finance ue, 17 Feb 2026 08
- Ugwumba Chidozie sells $403,084 of Clene Inc. stock - Investing.com Wed, 22 Apr 2026 22
- Major Clene Investor Makes Bold Move With Notable Stock Sale - TipRanks hu, 23 Apr 2026 02
- Clene (CLNN) Stock Low Volume (Pulls Back) 2026-04-20 - Volatility Breakout - Xã Thanh Hà Mon, 20 Apr 2026 15
- CLNN Forecast, Price Target & Analyst Ratings | CLENE INC (NASDAQ:CLNN) - ChartMill Fri, 17 Apr 2026 07
- $CLNN stock is down 19% today. Here's what we see in our data. - Quiver Quantitative Mon, 12 Jan 2026 08
- Clene (CLNN) Stock Low Volume (Pulls Back) 2026-04-20 - Open Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La Mon, 20 Apr 2026 15
- Is Clene (CLNN) stock worth entering at this stage | Q4 2025: EPS Misses Estimates - Analyst Recommended Stocks - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 00
- Clene Inc. (CLNN) major holder sells 39,162 common shares - Stock Titan Sat, 18 Apr 2026 00
- Ugwumba Chidozie sells $403,084 of Clene Inc. stock By Investing.com - Investing.com South Africa Wed, 22 Apr 2026 22
- Insider Purchase: Director at $CLNN Buys 33,333 Shares - Quiver Quantitative ue, 13 Jan 2026 08
- Experimental ALS drug CNM-Au8 heads toward 2026 FDA review - Stock Titan ue, 24 Feb 2026 08
- Ugwumba Chidozie sells $403,084 of Clene Inc. stock By Investing.com - Investing.com Australia Wed, 22 Apr 2026 22
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.20
-41.52%
|
0.34
-47.71%
|
0.65
+38.27%
|
0.47
|
| Operating Revenue |
|
0.20
-41.52%
|
0.34
-47.71%
|
0.65
+38.27%
|
0.47
|
| Cost Of Revenue |
|
0.04
-38.57%
|
0.07
-42.15%
|
0.12
+365.38%
|
0.03
|
| Reconciled Cost Of Revenue |
|
0.04
-38.57%
|
0.07
-42.15%
|
0.12
+365.38%
|
0.03
|
| Gross Profit |
|
0.16
-42.28%
|
0.27
-48.97%
|
0.53
+19.24%
|
0.45
|
| Operating Expense |
|
21.97
-31.86%
|
32.25
-16.87%
|
38.79
-13.80%
|
45.00
|
| Research And Development |
|
14.01
-30.15%
|
20.06
-24.75%
|
26.66
-16.49%
|
31.92
|
| Selling General And Administration |
|
8.43
-32.16%
|
12.43
-3.17%
|
12.83
-20.60%
|
16.16
|
| General And Administrative Expense |
|
8.43
-32.16%
|
12.43
-3.17%
|
12.83
-20.60%
|
16.16
|
| Salaries And Wages |
|
6.27
-26.97%
|
8.58
-7.65%
|
9.29
-6.08%
|
9.90
|
| Other Gand A |
|
1.44
-52.47%
|
3.02
+55.24%
|
1.95
-32.22%
|
2.87
|
| Other Operating Expenses |
|
-0.61
-21.43%
|
-0.50
+47.66%
|
-0.96
+68.72%
|
-3.08
|
| Total Expenses |
|
22.02
-31.87%
|
32.32
-16.95%
|
38.91
-13.58%
|
45.03
|
| Operating Income |
|
-21.82
+31.77%
|
-31.98
+16.43%
|
-38.26
+14.13%
|
-44.56
|
| Total Operating Income As Reported |
|
-23.08
+30.25%
|
-33.09
+18.37%
|
-40.54
+16.26%
|
-48.41
|
| EBITDA |
|
-22.00
+34.71%
|
-33.69
+22.09%
|
-43.24
-68.89%
|
-25.60
|
| Normalized EBITDA |
|
-21.11
+35.00%
|
-32.48
+37.60%
|
-52.05
-18.15%
|
-44.05
|
| Reconciled Depreciation |
|
1.50
-9.12%
|
1.65
-3.52%
|
1.71
+67.32%
|
1.02
|
| EBIT |
|
-23.49
+33.52%
|
-35.34
+21.38%
|
-44.95
-68.83%
|
-26.62
|
| Total Unusual Items |
|
-0.89
+26.92%
|
-1.21
-113.75%
|
8.81
-52.27%
|
18.45
|
| Total Unusual Items Excluding Goodwill |
|
-0.89
+26.92%
|
-1.21
-113.75%
|
8.81
-52.27%
|
18.45
|
| Special Income Charges |
|
0.00
+100.00%
|
-0.13
-105.22%
|
2.47
-86.49%
|
18.28
|
| Other Special Charges |
|
—
|
0.21
|
—
|
-0.42
|
| Restructuring And Mergern Acquisition |
|
0.00
+100.00%
|
-0.09
+96.56%
|
-2.47
+86.17%
|
-17.86
|
| Net Income |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Pretax Income |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Net Non Operating Interest Income Expense |
|
-3.47
+12.32%
|
-3.96
+11.73%
|
-4.49
-16.70%
|
-3.84
|
| Interest Expense Non Operating |
|
2.68
-34.01%
|
4.06
-10.84%
|
4.56
+38.29%
|
3.30
|
| Net Interest Income |
|
-3.47
+12.32%
|
-3.96
+11.73%
|
-4.49
-16.70%
|
-3.84
|
| Interest Expense |
|
2.68
-34.01%
|
4.06
-10.84%
|
4.56
+38.29%
|
3.30
|
| Interest Income Non Operating |
|
0.22
-74.22%
|
0.86
-37.72%
|
1.39
+517.33%
|
0.23
|
| Interest Income |
|
0.22
-74.22%
|
0.86
-37.72%
|
1.39
+517.33%
|
0.23
|
| Other Income Expense |
|
-0.89
+74.47%
|
-3.47
+48.71%
|
-6.76
-136.56%
|
18.48
|
| Other Non Operating Income Expenses |
|
—
|
-2.25
+85.51%
|
-15.56
-48740.63%
|
0.03
|
| Gain On Sale Of Security |
|
-0.89
+18.21%
|
-1.08
-117.07%
|
6.34
+3649.70%
|
0.17
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Net Income From Continuing And Discontinued Operation |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Net Income Continuous Operations |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Normalized Income |
|
-25.29
+33.78%
|
-38.19
+34.51%
|
-58.31
-20.55%
|
-48.37
|
| Net Income Common Stockholders |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Diluted EPS |
|
-2.65
+53.26%
|
-5.67
+39.87%
|
-9.43
-2.50%
|
-9.20
|
| Basic EPS |
|
-2.65
+53.26%
|
-5.67
+39.87%
|
-9.43
-2.50%
|
-9.20
|
| Basic Average Shares |
|
9.86
+41.77%
|
6.95
+32.54%
|
5.25
+60.94%
|
3.26
|
| Diluted Average Shares |
|
9.86
+41.77%
|
6.95
+32.54%
|
5.25
+60.94%
|
3.26
|
| Diluted NI Availto Com Stockholders |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Depreciation Amortization Depletion Income Statement |
|
0.14
-45.86%
|
0.27
-0.37%
|
0.27
|
—
|
| Depreciation And Amortization In Income Statement |
|
0.14
-45.86%
|
0.27
-0.37%
|
0.27
|
—
|
| Depreciation Income Statement |
|
0.14
-45.86%
|
0.27
-0.37%
|
0.27
|
—
|
| Insurance And Claims |
|
0.72
-11.80%
|
0.82
-48.40%
|
1.59
-53.08%
|
3.40
|
| Total Other Finance Cost |
|
1.01
+33.11%
|
0.76
-42.22%
|
1.32
+70.38%
|
0.77
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
52.34
|
| Current Assets |
|
38.85
|
| Cash Cash Equivalents And Short Term Investments |
|
35.00
|
| Cash And Cash Equivalents |
|
28.82
|
| Cash Equivalents |
|
25.00
|
| Cash Financial |
|
3.82
|
| Other Short Term Investments |
|
6.18
|
| Receivables |
|
1.34
|
| Accounts Receivable |
|
0.14
|
| Other Receivables |
|
—
|
| Taxes Receivable |
|
1.20
|
| Inventory |
|
0.04
|
| Raw Materials |
|
0.02
|
| Finished Goods |
|
0.01
|
| Prepaid Assets |
|
1.91
|
| Other Current Assets |
|
0.57
|
| Total Non Current Assets |
|
13.49
|
| Net PPE |
|
13.43
|
| Gross PPE |
|
20.32
|
| Accumulated Depreciation |
|
-6.89
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.64
|
| Construction In Progress |
|
1.44
|
| Other Properties |
|
8.26
|
| Leases |
|
9.98
|
| Other Non Current Assets |
|
0.06
|
| Total Liabilities Net Minority Interest |
|
38.95
|
| Current Liabilities |
|
25.33
|
| Payables And Accrued Expenses |
|
2.67
|
| Payables |
|
1.50
|
| Accounts Payable |
|
1.50
|
| Current Accrued Expenses |
|
1.16
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.12
|
| Current Debt And Capital Lease Obligation |
|
20.11
|
| Current Debt |
|
19.50
|
| Other Current Borrowings |
|
19.50
|
| Current Capital Lease Obligation |
|
0.60
|
| Current Deferred Liabilities |
|
0.44
|
| Current Deferred Revenue |
|
0.44
|
| Total Non Current Liabilities Net Minority Interest |
|
13.62
|
| Long Term Debt And Capital Lease Obligation |
|
12.05
|
| Long Term Debt |
|
7.15
|
| Long Term Capital Lease Obligation |
|
4.90
|
| Other Non Current Liabilities |
|
0.09
|
| Stockholders Equity |
|
13.39
|
| Common Stock Equity |
|
13.39
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Share Issued |
|
6.42
|
| Ordinary Shares Number |
|
6.42
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
255.91
|
| Retained Earnings |
|
-242.72
|
| Gains Losses Not Affecting Retained Earnings |
|
0.20
|
| Other Equity Adjustments |
|
0.20
|
| Total Equity Gross Minority Interest |
|
13.39
|
| Total Capitalization |
|
20.54
|
| Working Capital |
|
13.52
|
| Invested Capital |
|
40.05
|
| Total Debt |
|
32.16
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
5.51
|
| Net Tangible Assets |
|
13.39
|
| Tangible Book Value |
|
13.39
|
| Derivative Product Liabilities |
|
1.48
|
| Other Inventories |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-18.55
+13.04%
|
-21.33
+29.32%
|
-30.17
+22.66%
|
-39.01
|
| Cash Flow From Continuing Operating Activities |
|
-18.55
+13.04%
|
-21.33
+29.32%
|
-30.17
+22.66%
|
-39.01
|
| Net Income From Continuing Operations |
|
-26.17
+33.57%
|
-39.40
+20.41%
|
-49.50
-65.47%
|
-29.92
|
| Depreciation Amortization Depletion |
|
1.50
-9.12%
|
1.65
-3.52%
|
1.71
+67.32%
|
1.02
|
| Depreciation |
|
1.50
-9.12%
|
1.65
-3.52%
|
1.71
+67.32%
|
1.02
|
| Depreciation And Amortization |
|
1.50
-9.12%
|
1.65
-3.52%
|
1.71
+67.32%
|
1.02
|
| Other Non Cash Items |
|
2.22
-41.88%
|
3.82
-74.63%
|
15.04
+188.89%
|
-16.92
|
| Stock Based Compensation |
|
6.38
-19.75%
|
7.95
-12.77%
|
9.12
+7.10%
|
8.51
|
| Operating Gains Losses |
|
0.89
-38.92%
|
1.45
+122.87%
|
-6.34
-3694.61%
|
-0.17
|
| Gain Loss On Investment Securities |
|
0.89
-18.13%
|
1.08
+117.06%
|
-6.34
-3694.61%
|
-0.17
|
| Gain Loss On Sale Of PPE |
|
0.00
-100.00%
|
0.15
|
0.00
|
—
|
| Change In Working Capital |
|
-3.35
-204.42%
|
3.21
+1781.15%
|
-0.19
+87.60%
|
-1.54
|
| Change In Receivables |
|
0.06
-18.99%
|
0.08
+71.74%
|
0.05
+132.86%
|
-0.14
|
| Changes In Account Receivables |
|
0.06
-18.99%
|
0.08
+71.74%
|
0.05
+132.86%
|
-0.14
|
| Change In Inventory |
|
0.03
+200.00%
|
-0.03
-616.67%
|
0.01
+400.00%
|
-0.00
|
| Change In Prepaid Assets |
|
0.12
+160.10%
|
-0.20
-110.02%
|
1.98
+236.94%
|
-1.44
|
| Change In Payables And Accrued Expense |
|
-2.57
-167.87%
|
3.78
+328.80%
|
-1.65
-407.25%
|
0.54
|
| Change In Accrued Expense |
|
-2.22
-154.84%
|
4.05
+2929.37%
|
-0.14
-156.52%
|
0.25
|
| Change In Payable |
|
-0.35
-31.82%
|
-0.26
+82.52%
|
-1.51
-629.82%
|
0.28
|
| Change In Account Payable |
|
-0.35
-31.82%
|
-0.26
+82.52%
|
-1.51
-629.82%
|
0.28
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-1.00
-137.53%
|
-0.42
+25.62%
|
-0.57
-14.81%
|
-0.49
|
| Investing Cash Flow |
|
-0.04
-100.62%
|
6.32
+521.35%
|
-1.50
+85.25%
|
-10.16
|
| Cash Flow From Continuing Investing Activities |
|
-0.04
-100.62%
|
6.32
+521.35%
|
-1.50
+85.25%
|
-10.16
|
| Net PPE Purchase And Sale |
|
-0.04
-160.00%
|
-0.01
+95.45%
|
-0.33
+93.63%
|
-5.18
|
| Purchase Of PPE |
|
-0.04
-160.00%
|
-0.01
+95.45%
|
-0.33
+93.63%
|
-5.18
|
| Capital Expenditure |
|
-0.04
-160.00%
|
-0.01
+95.45%
|
-0.33
+93.63%
|
-5.18
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
6.33
+641.57%
|
-1.17
+76.55%
|
-4.99
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-6.17
+0.00%
|
-6.17
+74.94%
|
-24.61
|
| Sale Of Investment |
|
0.00
-100.00%
|
12.50
+150.00%
|
5.00
-74.53%
|
19.63
|
| Financing Cash Flow |
|
11.52
+853.30%
|
-1.53
-103.63%
|
42.16
+144.44%
|
17.25
|
| Cash Flow From Continuing Financing Activities |
|
11.52
+853.30%
|
-1.53
-103.63%
|
42.16
+144.44%
|
17.25
|
| Net Issuance Payments Of Debt |
|
1.12
+110.24%
|
-10.90
-4150.56%
|
0.27
-95.16%
|
5.56
|
| Issuance Of Debt |
|
1.50
-84.89%
|
9.92
+2735.43%
|
0.35
-93.85%
|
5.70
|
| Repayment Of Debt |
|
-0.38
+98.16%
|
-20.82
-25603.70%
|
-0.08
+40.00%
|
-0.14
|
| Long Term Debt Issuance |
|
1.50
-84.89%
|
9.92
+2735.43%
|
0.35
-93.85%
|
5.70
|
| Long Term Debt Payments |
|
-0.38
+98.16%
|
-20.82
-25603.70%
|
-0.08
+40.00%
|
-0.14
|
| Net Long Term Debt Issuance |
|
1.12
+110.24%
|
-10.90
-4150.56%
|
0.27
-95.16%
|
5.56
|
| Net Common Stock Issuance |
|
10.40
+12.54%
|
9.24
-78.04%
|
42.09
+267.31%
|
11.46
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.12
|
0.00
-100.00%
|
0.31
|
| Net Other Financing Charges |
|
—
|
—
|
-0.20
-146.91%
|
-0.08
|
| Changes In Cash |
|
-7.07
+57.27%
|
-16.54
-257.62%
|
10.49
+132.87%
|
-31.93
|
| Effect Of Exchange Rate Changes |
|
0.10
+179.53%
|
-0.13
-3075.00%
|
-0.00
+86.67%
|
-0.03
|
| Beginning Cash Position |
|
12.21
-57.71%
|
28.88
+57.04%
|
18.39
-63.47%
|
50.35
|
| End Cash Position |
|
5.25
-57.04%
|
12.21
-57.71%
|
28.88
+57.04%
|
18.39
|
| Free Cash Flow |
|
-18.59
+12.91%
|
-21.34
+30.03%
|
-30.50
+30.98%
|
-44.19
|
| Interest Paid Supplemental Data |
|
1.04
-60.08%
|
2.61
-14.58%
|
3.06
+31.85%
|
2.32
|
| Change In Income Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Change In Tax Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
10.40
+12.54%
|
9.24
-78.04%
|
42.09
+267.31%
|
11.46
|
| Issuance Of Capital Stock |
|
10.40
+12.54%
|
9.24
-78.04%
|
42.09
+267.31%
|
11.46
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-22 View
- 42026-04-17 View
- 42026-04-06 View
- 42026-04-01 View
- 42026-03-31 View
- 42026-03-26 View
- 10-K2026-03-17 View
- 8-K2026-03-17 View
- 8-K2026-03-12 View
- 8-K2026-02-24 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-05 View
- 42026-02-02 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|